Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF), the most common form of idiopathic interstitial pneumonia (IIP), is characterized by irreversible scarring of the lung parenchyma and progressive decline in lung function leading to eventual respiratory failure. The prognosis of IPF is poor with a median survival of three to five years after diagnosis and no curative medical therapies. Though the pathogenesis of IPF is not sufficiently knownnot well understood, there is a increasing growing body of evidence that genetic factors predispose individuals to develop IPFcontribute to disease risk. Recent studies have identified common and rare genetic variants associated with both sporadic and familial forms of pulmonary fibrosis, with at least . Current data suggests that at least one-third of the risk for developing fibrotic IIP and IPF can be explained by common genetic variants. In addition, some common variants have also been associated with distinct clinical phenotypes. The IPF-associated genetic loci discovered to date are associated with IPF are implicated in diverse biological processes, including alveolar stability, host defense, cell-cell barrier function, and cell senescence. In addition, some common variants have also been associated with distinct clinical phenotypes. Identification of gene variants associated with IPF and with IPF-associated mortalityBetter understanding of how genetic variation plays a role in disease risk and phenotype could identify potential therapeutic targets and inform clinical decision-making. Future In addition, clinical studies should be designed controlling for the genetic backgrounds of subjects, since disease phenotype and clinical outcomes and therapeutic responses may differ by genotype. Further understanding of these differences will allow the development of a personalized approaches to the IPF management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 5×
“During successive cycles of cell division, telomere shortening occurs and eventually leads to activation of the DNA-damage pathways, which result in apoptosis or senescence (32).”
BackgroundInfluentialArmanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982 · cited 1×
“Defects in telomere maintenance have been linked to epithelial cell senescence and an impaired response to epithelial injury (65).”
BackgroundHeiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, A., & Dokal, I. (1998) · Nature Genetics · doi:10.1038/ng0598-32 · Cited by 976 · cited 1×
“in telomerase complex Telomere shortening (19, 27, 38)”
BackgroundA Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial Lung Disease
Nogee, L. M., Dunbar, A. E., Wert, S. E., Askin, F., Hamvas, A., & Whitsett, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440805 · Cited by 929
Adult-onset pulmonary fibrosis caused by mutations in telomerase
Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., & Garcia, C. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701009104 · Cited by 894 · cited 5×
“Am J Respir Crit Care Med (2008) 178(7):729–37.”
BackgroundInfluentialGenome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Self-citationShort telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804280105 · Cited by 805 · cited 2×
“Short telomeres (<10th percentile adjusted for age) have been identified in a considerable portion of IPF patients, regardless of genetic mutations (33, 34).”
BackgroundMuc5b is required for airway defence
Roy, M. G., Livraghi-Butrico, A., Fletcher, A. A., McElwee, M. M., Evans, S. E., Boerner, R. M., Alexander, S. N., Bellinghausen, L. K., Song, A. S., Petrova, Y. M., et al. (2014) · Nature · doi:10.1038/nature12807 · Cited by 764 · cited 2×
“Given that mucins play a role in innate immunity (68, 83), immune dysregulation could be a possible mechanism by which increased mucin expression contributes to the pathophysiology of IPF (84).”
BackgroundSelf-citation
Cited by
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis
Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B., & Staab-Weijnitz, C. A. (2022) · Cells · doi:10.3390/cells11061050 · Cited by 68
Modelling and targeting mechanical forces in organ fibrosis
Mascharak, S., L. Guo, J., Griffin, M., E. Berry, C., C. Wan, D., & T. Longaker, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00144-3 · Cited by 59
“Innate and adaptive immune responses, infectious organisms (such as viruses or helminths) and genetic factors (for example telomerase mutations in idiopathic pulmonary fibrosis) have been implicated as important drivers of fibrosis 6,7 .”
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
Metadata
- Authors
- Kaur, A., Mathai, S. K., & Schwartz, D. A.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-09-25
- Volume
- 4
- Pages
- 154-154
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2757116276
- Cited by
- 129
- References
- 23
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.